Status:
COMPLETED
Optimum Platelet Inhibition After Coronary Bypass Surgery
Lead Sponsor:
Papworth Hospital NHS Foundation Trust
Conditions:
Ischemic Heart Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To investigate the effect of different dosages of aspirin on platelet aggregation and to determine the possible mechanisms of aspirin resistance, we intend to compare the effects of low, medium dose a...
Eligibility Criteria
Inclusion
- We intend to invite patients aged 18 to 80 proceeding to primary elective coronary artery bypass surgery, able to give informed consent.
Exclusion
- Preoperative exclusion criteria:
- patients who are have not stopped aspirin 7 days prior to surgery
- patients on concomitant NSAIDS
- patients with a previous history platelet disorders, splenectomy or haematological disorders
- patients with aspirin induced asthma
- patients with any contraindications to aspirin (GI bleed)
- patients who are on any medication that may result in a serious drug interaction with aspirin (warfarin)
- Women of childbearing potential
- Patients of less than 18 years
- If informed consent cannot be obtained
- If for any reason the consultant surgeon or anaesthetist deems it to be appropriate
- Operative exclusion criteria:
- • Concomitant procedures
- Postoperative exclusion criteria:
- patients who receive platelet transfusion
- patients who receive NSAIDS
- requirement for intra aortic balloon pump support
- failure of extubation within 24 hours
Key Trial Info
Start Date :
July 1 2002
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00262275
Start Date
July 1 2002
Last Update
January 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Papworth Hospital
Cambridge, United Kingdom, CB3 8RE